Dissolution enhancement of celecoxib via polymer-induced crystallization
Source abstract
Abstract
Abstract Pharmaceutical research and development critically rely on crystallization engineering principles since they influence the bioavailability, stability and processability of drug formulations. Although the polymer-induced crystallization has been intensively investigated in the area of inorganic materials, drug molecules have seldom been its subject. Celecoxib, which critically needed the improvement of bioavailability and processability, benefited from polymer-induced crystallization. Polyvinylpyrrolidone (PVP) and Pluronic successfully reduced the aspect ratio of celecoxib crystals to 1.5, which would improve processability. Among the polymers used, PVP distinctly improved the in vitro drug release behavior, which is consistent with the significant melting point depression and the polymorphic change in celecoxib crystallized with PVP. The strong hydrogen bonding between celecoxib and PVP is suspected as the origin of the improved crystal morphology and in vitro drug release. This polymer-induced crystallization can create new opportunities of convenient pharmaceutical particle engineering allowing reliable improvements in bioavailability and processability.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Crystallization and Solubility Studies · Crystallography and molecular interactions · Calcium Carbonate Crystallization and Inhibition
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Impact of solid state properties on developability assessment of drug candidates10.1016/j.addr.2003.10.007 ↗
2. New form discovery for the analgesics flurbiprofen and sulindac facilitated by polymer‐induced heteronucleation10.1002/jps.20954 ↗
3. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids10.1016/j.addr.2003.10.020 ↗
4. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion10.1016/j.ejps.2004.12.010 ↗
5. Drug nano‐and microparticles processed into solid dosage forms: physical properties10.1002/jps.10471 ↗
6. Role of the prestructured surface cloud in crystal nucleation10.1103/PhysRevLett.106.085701 ↗
7. Crystal nucleation: in a tight corner10.1038/nmat3157 ↗
8. Oriented attachment and mesocrystals: non-classical crystallization mechanisms based on nanoparticle assembly10.1039/B604589H ↗
9. Mesocrystals—ordered nanoparticle superstructures10.1002/adma.200901365 ↗
10. Bio-inspired mineralization using hydrophilic polymers
11. Stable prenucleation calcium carbonate clusters10.1126/science.1164271 ↗
12. Crystalline, porous microspheres made from amino acids by using polymer-induced liquid precursor phases10.1002/anie.200462467 ↗
13. Dissolution enhancement by bio-inspired mesocrystals: the study of racemic (R, S)-(±)-sodium ibuprofen dihydrate10.1007/s11095-008-9554-y ↗
14. Prevention of crystal growth in acetaminophen suspensions by the use of polyvinyl pyrrolidone and bovine serum albumin
15. Crystallization of hydrocortisone acetate: influence of polymers10.1016/S0378-5173(00)00610-4 ↗
16. Polymer‐directed crystallization of atorvastatin10.1002/jps.23206 ↗
17. Characterization of solid-state forms of celecoxib10.1016/S0928-0987(03)00201-X ↗
18. Celecoxib sodium salt: engineering crystal forms for performance10.1039/C0CE00475H ↗
19. Role of α-relaxation on crystallization of amorphous celecoxib above Tg probed by dielectric spectroscopy10.1021/mp100411v ↗
20. Celecoxib: nicotinamide dissociation: using excipients to capture the cocrystal's potential10.1021/mp0700108 ↗
21. Influence of solvents on the crystal habit and properties of rofecoxib and celecoxib: no evidence of polymorphism10.4103/0976-9234.75704 ↗
22. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective10.1023/B:PHAM.0000045226.42859.b8 ↗
23. H. Gunduz, M. Bahar, M. Goktepe, Crystals of Celecoxib, in, Google Patents, 2002.
24. L.J. Ferro, P.S. Miyake, Polymorphic Crystalline forms of Celecoxib, in, Google Patents, 2009.
25. Characterization of a novel polymorphic form of celecoxib10.1002/jps.20522 ↗
26. The use of spray-drying to enhance celecoxib solubility10.3109/03639045.2011.587428 ↗
27. Melting of nanostructured drugs embedded into a polymeric matrix10.1021/jp048762u ↗
28. Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery
29. Control of drug crystallization in transdermal matrix system10.1016/0378-5173(96)04647-9 ↗
30. Size effect on melting temperature of nanostructured drugs10.1016/j.matchemphys.2007.01.014 ↗
31. Nanoscale thermal analysis of pharmaceutical solid dispersions10.1016/j.ijpharm.2009.07.003 ↗
32. Thermal conductivity of a graphene oxide–carbon nanotube hybrid/epoxy composite10.1016/j.carbon.2012.07.029 ↗
33. Surface energy engineered, high-resolution micropatterning of solution-processed reduced graphene oxide thin films10.1002/adma.201203881 ↗
34. Increased work function in few-layer graphene sheets via metal chloride doping10.1002/adfm.201200997 ↗